Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4.444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
Lancet, 344 (1994), pp. 1383-1389
[2.]
T.J. Wang, R.S. Stafford, J.C. Ausiello, C.E. Chaisson.
Randomized clinical trials and recent patterns in the use of statins.
Am Heart J, 141 (2001), pp. 957-963
[3.]
J. Shepherd, S.M. Cobbe, I. Ford, C.G. Isles, A.R. Lorimer, P.W. Macfarlane, et al.
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
N Engl J Med, 333 (1995), pp. 1301-1307
[4.]
F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, T.G. Cole, et al.
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
N Engl J Med, 335 (1996), pp. 1001-1009
[5.]
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
N Engl J Med, 339 (1998), pp. 1349-1357
[6.]
D. Wood, G. De Backer, O. Faergeman, I. Graham, G. Mancia, K. Pyörälä, et al.
Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention.
Atherosclerosis, 140 (1998), pp. 199-270
[7.]
Anónimo.
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
Jama, 285 (2001), pp. 2486-2497
[8.]
C.D. Furberg, B. Pitt.
Withdrawal of cerivastatin from the world market.
Curr Control Trials Cardiovasc Med, 2 (2001), pp. 205-207
[9.]
P.R. Herbert, J.M. Graziano, K.S. Chan, C.H. Hennekens.
Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials.
Jama, 278 (1997), pp. 313-321
[10.]
Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT (consultado el 15 de octubre de 2003). Disponible en http://www.ascotstudy.co.uk
[11.]
L. Wilhemsen, K. Pyörälä, H. Wedel, T. Cook, T. Pedersen, J. Kjekshus, et al.
Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment.
Eur Heart J, 22 (2001), pp. 1119-1127
[12.]
P.S. Sever, B. Dahlöf, N.R. Poulter, H. Wedel, G. Beevers, M. Caulfield, et al.
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
Lancet, 361 (2003), pp. 1149-1158
Copyright © 2004. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.